Hepatic resection for metachronous metastases from ovarian carcinoma

Melissa A. Merideth, William Arthur Cliby, Gary Keeney, Timothy G. Lesnick, David M. Nagorney, Karl C. Podratz

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective. Hepatic resection for recurrent ovarian carcinoma is controversial because of the paucity of relevant published data. The principles of cytoreduction before chemotherapy suggest that resection of measurable liver lesions in properly selected patients would be beneficial. To determine the effect of resection of metachronous liver metastases on morbidity and survival, we reviewed our experience with this treatment. Methods. Medical records were reviewed retrospectively for all patients who had anatomic hepatic resection for metachronous parenchymal liver metastases from ovarian carcinoma (epithelial or malignant mixed Müllerian tumors) at Mayo Clinic from 1976 to 1999. Results. We identified 26 patients (median age at hepatic resection, 62 years; range, 39-75 years) who had hepatic resection requiring complete segmentectomies or more extensive hepatic surgery for recurrent ovarian carcinoma. Cytoreduction was optimal (extrahepatic and hepatic residual disease ≤1 cm) in 21 patients and suboptimal in 5. No intraoperative or postoperative deaths occurred. Aside from blood loss requiring transfusion of more than 4 units of erythrocytes in 4 patients, only two complications were noted: one superficial wound infection and one small-bowel perforation that required reoperation. The overall median disease-related survival was 26.3 months after hepatic resection; 18 patients (69%) died of disease at a median of 14.6 months (range, 5.0-41.3 months). However, 8 patients (31%) were alive at median follow-up of 33.2 months (range, 3.6-49.6 months). Factors significantly associated with improved disease-related survival were consistent with known prognostic factors associated with cytoreductive surgery, including more than 12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004) and less than or equal to 1 cm of residual disease after hepatic resection (27.3 vs 8.6 months, P = 0.031). Conclusion. We present evidence that hepatic resection can be performed with minimal surgical morbidity and mortality by surgical teams trained in the procedures. Because of the disease-related survival advantage afforded women by optimal cytoreductive surgery, parenchymal liver metastases should not preclude secondary cytoreductive surgical efforts.

Original languageEnglish (US)
Pages (from-to)16-21
Number of pages6
JournalGynecologic Oncology
Volume89
Issue number1
DOIs
StatePublished - Apr 1 2003

Fingerprint

Neoplasm Metastasis
Carcinoma
Liver
Survival
Malignant Mixed Tumor
Morbidity
Segmental Mastectomy
Wound Infection
Reoperation
Medical Records
Erythrocytes
Drug Therapy
Mortality

Keywords

  • Cytoreduction
  • Liver
  • Morbidity
  • Mortality
  • Retrospective study

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Hepatic resection for metachronous metastases from ovarian carcinoma. / Merideth, Melissa A.; Cliby, William Arthur; Keeney, Gary; Lesnick, Timothy G.; Nagorney, David M.; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 89, No. 1, 01.04.2003, p. 16-21.

Research output: Contribution to journalArticle

Merideth, Melissa A. ; Cliby, William Arthur ; Keeney, Gary ; Lesnick, Timothy G. ; Nagorney, David M. ; Podratz, Karl C. / Hepatic resection for metachronous metastases from ovarian carcinoma. In: Gynecologic Oncology. 2003 ; Vol. 89, No. 1. pp. 16-21.
@article{2808113849a642f4836c20766220eca5,
title = "Hepatic resection for metachronous metastases from ovarian carcinoma",
abstract = "Objective. Hepatic resection for recurrent ovarian carcinoma is controversial because of the paucity of relevant published data. The principles of cytoreduction before chemotherapy suggest that resection of measurable liver lesions in properly selected patients would be beneficial. To determine the effect of resection of metachronous liver metastases on morbidity and survival, we reviewed our experience with this treatment. Methods. Medical records were reviewed retrospectively for all patients who had anatomic hepatic resection for metachronous parenchymal liver metastases from ovarian carcinoma (epithelial or malignant mixed M{\"u}llerian tumors) at Mayo Clinic from 1976 to 1999. Results. We identified 26 patients (median age at hepatic resection, 62 years; range, 39-75 years) who had hepatic resection requiring complete segmentectomies or more extensive hepatic surgery for recurrent ovarian carcinoma. Cytoreduction was optimal (extrahepatic and hepatic residual disease ≤1 cm) in 21 patients and suboptimal in 5. No intraoperative or postoperative deaths occurred. Aside from blood loss requiring transfusion of more than 4 units of erythrocytes in 4 patients, only two complications were noted: one superficial wound infection and one small-bowel perforation that required reoperation. The overall median disease-related survival was 26.3 months after hepatic resection; 18 patients (69{\%}) died of disease at a median of 14.6 months (range, 5.0-41.3 months). However, 8 patients (31{\%}) were alive at median follow-up of 33.2 months (range, 3.6-49.6 months). Factors significantly associated with improved disease-related survival were consistent with known prognostic factors associated with cytoreductive surgery, including more than 12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004) and less than or equal to 1 cm of residual disease after hepatic resection (27.3 vs 8.6 months, P = 0.031). Conclusion. We present evidence that hepatic resection can be performed with minimal surgical morbidity and mortality by surgical teams trained in the procedures. Because of the disease-related survival advantage afforded women by optimal cytoreductive surgery, parenchymal liver metastases should not preclude secondary cytoreductive surgical efforts.",
keywords = "Cytoreduction, Liver, Morbidity, Mortality, Retrospective study",
author = "Merideth, {Melissa A.} and Cliby, {William Arthur} and Gary Keeney and Lesnick, {Timothy G.} and Nagorney, {David M.} and Podratz, {Karl C.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0090-8258(03)00004-0",
language = "English (US)",
volume = "89",
pages = "16--21",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Hepatic resection for metachronous metastases from ovarian carcinoma

AU - Merideth, Melissa A.

AU - Cliby, William Arthur

AU - Keeney, Gary

AU - Lesnick, Timothy G.

AU - Nagorney, David M.

AU - Podratz, Karl C.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Objective. Hepatic resection for recurrent ovarian carcinoma is controversial because of the paucity of relevant published data. The principles of cytoreduction before chemotherapy suggest that resection of measurable liver lesions in properly selected patients would be beneficial. To determine the effect of resection of metachronous liver metastases on morbidity and survival, we reviewed our experience with this treatment. Methods. Medical records were reviewed retrospectively for all patients who had anatomic hepatic resection for metachronous parenchymal liver metastases from ovarian carcinoma (epithelial or malignant mixed Müllerian tumors) at Mayo Clinic from 1976 to 1999. Results. We identified 26 patients (median age at hepatic resection, 62 years; range, 39-75 years) who had hepatic resection requiring complete segmentectomies or more extensive hepatic surgery for recurrent ovarian carcinoma. Cytoreduction was optimal (extrahepatic and hepatic residual disease ≤1 cm) in 21 patients and suboptimal in 5. No intraoperative or postoperative deaths occurred. Aside from blood loss requiring transfusion of more than 4 units of erythrocytes in 4 patients, only two complications were noted: one superficial wound infection and one small-bowel perforation that required reoperation. The overall median disease-related survival was 26.3 months after hepatic resection; 18 patients (69%) died of disease at a median of 14.6 months (range, 5.0-41.3 months). However, 8 patients (31%) were alive at median follow-up of 33.2 months (range, 3.6-49.6 months). Factors significantly associated with improved disease-related survival were consistent with known prognostic factors associated with cytoreductive surgery, including more than 12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004) and less than or equal to 1 cm of residual disease after hepatic resection (27.3 vs 8.6 months, P = 0.031). Conclusion. We present evidence that hepatic resection can be performed with minimal surgical morbidity and mortality by surgical teams trained in the procedures. Because of the disease-related survival advantage afforded women by optimal cytoreductive surgery, parenchymal liver metastases should not preclude secondary cytoreductive surgical efforts.

AB - Objective. Hepatic resection for recurrent ovarian carcinoma is controversial because of the paucity of relevant published data. The principles of cytoreduction before chemotherapy suggest that resection of measurable liver lesions in properly selected patients would be beneficial. To determine the effect of resection of metachronous liver metastases on morbidity and survival, we reviewed our experience with this treatment. Methods. Medical records were reviewed retrospectively for all patients who had anatomic hepatic resection for metachronous parenchymal liver metastases from ovarian carcinoma (epithelial or malignant mixed Müllerian tumors) at Mayo Clinic from 1976 to 1999. Results. We identified 26 patients (median age at hepatic resection, 62 years; range, 39-75 years) who had hepatic resection requiring complete segmentectomies or more extensive hepatic surgery for recurrent ovarian carcinoma. Cytoreduction was optimal (extrahepatic and hepatic residual disease ≤1 cm) in 21 patients and suboptimal in 5. No intraoperative or postoperative deaths occurred. Aside from blood loss requiring transfusion of more than 4 units of erythrocytes in 4 patients, only two complications were noted: one superficial wound infection and one small-bowel perforation that required reoperation. The overall median disease-related survival was 26.3 months after hepatic resection; 18 patients (69%) died of disease at a median of 14.6 months (range, 5.0-41.3 months). However, 8 patients (31%) were alive at median follow-up of 33.2 months (range, 3.6-49.6 months). Factors significantly associated with improved disease-related survival were consistent with known prognostic factors associated with cytoreductive surgery, including more than 12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004) and less than or equal to 1 cm of residual disease after hepatic resection (27.3 vs 8.6 months, P = 0.031). Conclusion. We present evidence that hepatic resection can be performed with minimal surgical morbidity and mortality by surgical teams trained in the procedures. Because of the disease-related survival advantage afforded women by optimal cytoreductive surgery, parenchymal liver metastases should not preclude secondary cytoreductive surgical efforts.

KW - Cytoreduction

KW - Liver

KW - Morbidity

KW - Mortality

KW - Retrospective study

UR - http://www.scopus.com/inward/record.url?scp=0037386240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037386240&partnerID=8YFLogxK

U2 - 10.1016/S0090-8258(03)00004-0

DO - 10.1016/S0090-8258(03)00004-0

M3 - Article

C2 - 12694649

AN - SCOPUS:0037386240

VL - 89

SP - 16

EP - 21

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -